These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11472235)

  • 21. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA hairpin loops repress protein synthesis more strongly than hammerhead ribozymes.
    Drew HR; Lewy D; Conaty J; Rand KN; Hendry P; Lockett T
    Eur J Biochem; 1999 Nov; 266(1):260-73. PubMed ID: 10542074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary structure in solution of two anti-HIV-1 hammerhead ribozymes as investigated by two-dimensional 1H 500 MHz NMR spectroscopy in water.
    Sarma RH; Sarma MH; Rein R; Shibata M; Setlik RS; Ornstein RL; Kazim AL; Cairo A; Tomasi TB
    FEBS Lett; 1995 Jan; 357(3):317-23. PubMed ID: 7835436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells.
    Feng Y; Kong YY; Wang Y; Qi GR
    Biol Chem; 2001 Apr; 382(4):655-60. PubMed ID: 11405228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of structure in a long target RNA on ribozyme cleavage efficiency.
    Campbell TB; McDonald CK; Hagen M
    Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
    Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
    Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cleavage of the highly conserved hairpin-loop region of HIV-1 by synthetic ribozymes.
    Shimayama T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1993; (29):177-8. PubMed ID: 8247758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.
    Homann M; Tabler M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3951-7. PubMed ID: 7524030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly.
    Westaway SK; Larson GP; Li S; Zaia JA; Rossi JJ
    Nucleic Acids Symp Ser; 1995; (33):194-9. PubMed ID: 8643367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes.
    Sakamoto N; Wu CH; Wu GY
    J Clin Invest; 1996 Dec; 98(12):2720-8. PubMed ID: 8981917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral ribozymes. New jobs for ancient molecules.
    Menke A; Hobom G
    Mol Biotechnol; 1997 Aug; 8(1):17-33. PubMed ID: 9327395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retroviral delivery and anti-HIV testing of hammerhead ribozymes.
    Cagnon L; Rossi J
    Methods Mol Biol; 1997; 74():451-7. PubMed ID: 9204460
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes.
    Prislei S; Buonomo SB; Michienzi A; Bozzoni I
    RNA; 1997 Jun; 3(6):677-87. PubMed ID: 9174101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation of active ribozymes from an RNA pool of random sequences using an anchored substrate RNA.
    Ishizaka M; Ohshima Y; Tani T
    Biochem Biophys Res Commun; 1995 Sep; 214(2):403-9. PubMed ID: 7545903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects for antiviral ribozymes and deoxyribozymes.
    Peracchi A
    Rev Med Virol; 2004; 14(1):47-64. PubMed ID: 14716691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribozymes as antiviral agents.
    Bartolomé J; Castillo I; Carreño V
    Minerva Med; 2004 Feb; 95(1):11-24. PubMed ID: 15041923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional gene-discovery systems based on libraries of hammerhead and hairpin ribozymes and short hairpin RNAs.
    Sano M; Kato Y; Taira K
    Mol Biosyst; 2005 May; 1(1):27-35. PubMed ID: 16880960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.